Birgit Wilding - c/o Institute of Organic Chemistry, Graz University of Technology

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 53 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Data Table 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyová,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumüller

crossref（2025）

Cited0Views0Bibtex

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyova,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumueller

CANCER DISCOVERYno. 1 (2025): 119-138

Cited0Views0WOSBibtex

136 (PB124): Zongertinib (BI1810631), an Irreversible HER2 TKI Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers

R. Neumueller,B. Wilding, M. Augsten, A. Baum, K. Chylinski, I. Waizenegger,L. Woelflingseder,F. Solca,N. Kraut

European Journal of Cancer（2024）

Cited0Views0Bibtex

KRASmulti Inhibitor BI 3706674, an Orally Bioavailable, Direct Inhibitor of Diverse Oncogenic KRAS Variants Drives Tumor Regression in KRASG12V-driven Preclinical Models

Cancer Researchno. 6_Supplement (2024): 3321-3321

Cited0Views0Bibtex

Elucidating the Novel Mechanism of Action of VVD-065, an Allosteric Molecular Glue for the KEAP1-CUL3 E3-ligase Complex That Promotes NRF2 Degradation in NRF2-activated Cancers

MOLECULAR CANCER THERAPEUTICSno. 12 (2023)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn